June 10, 2013

New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults

New Fluzone® Quadrivalent (Influenza Virus Vaccine):

- The first and only 4-strain influenza vaccine option for patients as young as six months of age,
- Helps protect children and adults against additional influenza B strain,
​- Newest addition to the Fluzone family of influenza vaccines.

 

New Four-Strain Influenza Vaccine from Sanofi Pasteur Now Licensed By FDA for Broad Age Range of Children and Adults
New Fluzone® Quadrivalent (Influenza Virus Vaccine):

Lyon, France – June 10, 2013 – Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that the U.S. Food and Drug Administration has approved the supplemental biologics license application (sBLA) for licensure of its four-strain influenza vaccine, Fluzone Quadrivalent vaccine. Fluzone Quadrivalent vaccine is the newest addition to the Fluzone family of influenza vaccines. Like Sanofi Pasteur’s Fluzone vaccine, which is administered to more than 50 million people in the U.S. each year, Fluzone Quadrivalent vaccine is licensed for use in children six months of age and older, adolescents, and adults.